Quest Diagnostics delivered a solid Q2 2025 performance with a robust revenue ramp and resilient margins, underscoring its position as a premier US diagnostic information services provider. Revenue reached USD 2.761 billion, up 15.2% year over year and 4.1% quarter over quarter, supported by higher testing volumes and favorable mix across routine, nonroutine, and advanced clinical testing. Gross profit of USD 944 million yielded a gross margin of 34.2%, while operating income of USD 425 million produced an operating margin around 15.4% and EBITDA of USD 451 million (EBITDA margin ~16.3%). Net income was USD 281 million, translating to a net margin of approximately 10.2% and an EPS of USD 2.51 (USD 2.47 diluted).